Skip to content

Novel technology development to screen the early stage of dementia by olfactory function evaluation

Development of fNIRS medical device for early dementia screening and mobile dementia management app using olfactory and cognitive stimulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0006197
Enrollment
100
Registered
2021-05-27
Start date
2021-03-02
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : For normal, preclinical dementia, mild cognitive impairment, and dementia patients, the near-infrared light emitting part (LED) and the light receiving part (PD) were attached to the

Sponsors

Gwangju Institute of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Criteria for Selecting Research Subjects ? Adult men and women without a physical or mental history other than dementia (over 20 years old-under 100 years old) ? Normal person with no symptoms of dementia (severity level 0) ? Preclinical AD dementia patient (severity stage 1) or Patients with mild cognitive impairment (severe level 2) All subjects were those who performed MMSE, SNSB, PET-CT, MRI, fNIRS olfactory stimulation test, and ApoE gene test within 1 year.

Exclusion criteria

Exclusion criteria: ¦ Criteria for Excluding Research Subjects ? If it is judged that the experiment is impossible because you have not been able to sit still for more than 10 minutes ? In case the stimulus screen or the stimulus sound is not recognized due to insensitivity to sight or hearing ? If you are unable to walk alone due to a severe gait disorder ? When it is judged that walking and balance-related behavior experiments cannot be performed due to a high risk of falling ? Dementia patients with difficult daily life

Design outcomes

Primary

MeasureTime frame
Confirmation of the difference in near-infrared signal between the normal group and the preclinical Alzheimer's dementia patient group

Secondary

MeasureTime frame
fNIRS signal amplitude rate for each group;The ratio between fNIRS oxygen hemoglobin and reduced hemoglobin signals in each group

Countries

Korea, Republic of

Contacts

Public ContactJaewon Kim

Gwangju Institute of Science and Technology

polariswon@gist.ac.kr+82-2-715-2636

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 12, 2026